ES2381968T3 - 2,2'-ditio-bis(etanosulfonato) para su uso en la inhibición de la termoestesia anómala inducida por paclitaxel - Google Patents
2,2'-ditio-bis(etanosulfonato) para su uso en la inhibición de la termoestesia anómala inducida por paclitaxel Download PDFInfo
- Publication number
- ES2381968T3 ES2381968T3 ES03721972T ES03721972T ES2381968T3 ES 2381968 T3 ES2381968 T3 ES 2381968T3 ES 03721972 T ES03721972 T ES 03721972T ES 03721972 T ES03721972 T ES 03721972T ES 2381968 T3 ES2381968 T3 ES 2381968T3
- Authority
- ES
- Spain
- Prior art keywords
- taxane
- ethanesulfonate
- treatment
- bis
- paclitaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 title claims description 45
- 229930012538 Paclitaxel Natural products 0.000 title claims description 41
- 229960001592 paclitaxel Drugs 0.000 title claims description 41
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims description 41
- 230000002159 abnormal effect Effects 0.000 title claims description 8
- 230000005764 inhibitory process Effects 0.000 title claims description 8
- 229940123237 Taxane Drugs 0.000 abstract description 112
- 239000002246 antineoplastic agent Substances 0.000 abstract description 89
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract description 87
- 229940034982 antineoplastic agent Drugs 0.000 abstract description 72
- 229940079593 drug Drugs 0.000 abstract description 68
- 239000003814 drug Substances 0.000 abstract description 63
- 238000011282 treatment Methods 0.000 abstract description 61
- 238000002512 chemotherapy Methods 0.000 abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 19
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 16
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 201000011510 cancer Diseases 0.000 abstract description 10
- 230000000116 mitigating effect Effects 0.000 abstract description 10
- 230000002411 adverse Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 229960004316 cisplatin Drugs 0.000 description 35
- 206010029350 Neurotoxicity Diseases 0.000 description 32
- 206010044221 Toxic encephalopathy Diseases 0.000 description 32
- 231100000228 neurotoxicity Toxicity 0.000 description 32
- 230000007135 neurotoxicity Effects 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000036571 hydration Effects 0.000 description 17
- 238000006703 hydration reaction Methods 0.000 description 17
- 230000001988 toxicity Effects 0.000 description 17
- 231100000419 toxicity Toxicity 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 208000033808 peripheral neuropathy Diseases 0.000 description 15
- 210000001428 peripheral nervous system Anatomy 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 150000003057 platinum Chemical class 0.000 description 12
- 238000011260 co-administration Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 10
- 238000011269 treatment regimen Methods 0.000 description 10
- 230000000118 anti-neoplastic effect Effects 0.000 description 9
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 9
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 8
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 208000035824 paresthesia Diseases 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000005426 pharmaceutical component Substances 0.000 description 7
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
- 230000001934 delay Effects 0.000 description 6
- 229960003668 docetaxel Drugs 0.000 description 6
- SDNJNDFHCODQDQ-UHFFFAOYSA-N n-(2-ethylphenyl)-2-[[2-[(2-ethylphenyl)carbamoyl]phenyl]disulfanyl]benzamide Chemical compound CCC1=CC=CC=C1NC(=O)C1=CC=CC=C1SSC1=CC=CC=C1C(=O)NC1=CC=CC=C1CC SDNJNDFHCODQDQ-UHFFFAOYSA-N 0.000 description 6
- 208000027232 peripheral nervous system disease Diseases 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001767 chemoprotection Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 231100000862 numbness Toxicity 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
- 229960004562 carboplatin Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000012910 preclinical development Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 208000020764 Sensation disease Diseases 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012829 chemotherapy agent Substances 0.000 description 3
- 230000007012 clinical effect Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000019430 Motor disease Diseases 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229940124444 chemoprotective agent Drugs 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010071732 Retroperitoneal mass Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229950009278 dimesna Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- -1 dissolution aids Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229940108949 paclitaxel injection Drugs 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/135,975 US8710095B2 (en) | 2002-04-30 | 2002-04-30 | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US135975 | 2002-04-30 | ||
| PCT/US2003/013518 WO2003092675A1 (en) | 2002-04-30 | 2003-04-29 | Drugs for mitigating taxane-induced neurotoxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2381968T3 true ES2381968T3 (es) | 2012-06-04 |
Family
ID=29249584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03721972T Expired - Lifetime ES2381968T3 (es) | 2002-04-30 | 2003-04-29 | 2,2'-ditio-bis(etanosulfonato) para su uso en la inhibición de la termoestesia anómala inducida por paclitaxel |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8710095B2 (https=) |
| EP (1) | EP1503748B1 (https=) |
| JP (2) | JP5416327B2 (https=) |
| AT (1) | ATE554753T1 (https=) |
| AU (1) | AU2003225253B2 (https=) |
| CA (1) | CA2483857A1 (https=) |
| ES (1) | ES2381968T3 (https=) |
| WO (1) | WO2003092675A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US20090111735A1 (en) * | 2004-05-12 | 2009-04-30 | Bionumerik Pharmaceuticals, Inc. | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| EP1991237B1 (en) * | 2005-12-13 | 2015-02-25 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| EP2004175A4 (en) * | 2006-03-16 | 2010-12-15 | Bionumerik Pharmaceuticals Inc | COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE |
| CN101790377A (zh) * | 2007-08-31 | 2010-07-28 | 国立大学法人九州大学 | 抗癌剂导致的末梢神经障碍的预防或减轻剂 |
| CA2706378C (en) | 2007-11-20 | 2017-09-12 | Lankenau Institute For Medical Research | Disulfide chemotherapeutic agents and methods of use thereof |
| ES2476602T3 (es) * | 2008-03-14 | 2014-07-15 | Bionumerik Pharmaceuticals, Inc. | Composiciones y métodos quimioprotectores |
| CN102014891B (zh) * | 2008-03-14 | 2013-12-18 | 比奥纽默里克药物公司 | 增加癌症患者存活时间的化合物的组合物和使用方法 |
| CA2717181C (en) * | 2008-03-14 | 2013-10-15 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| US9320760B2 (en) * | 2008-03-14 | 2016-04-26 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| US20090232906A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| UY33203A (es) | 2010-01-27 | 2011-08-31 | Takeda Pharmaceutical | Medicamento que suprime (o mitiga) varios síntomas neurológicos originados por un trastorno del nervio periférico inducido por un agente anticancerígeno |
| US11471431B2 (en) * | 2010-09-16 | 2022-10-18 | Lantern Pharma Inc. | Increasing cancer patient survival time by administration of dithio-containing compounds |
| WO2015070323A1 (en) * | 2013-11-15 | 2015-05-21 | Oncolytics Biotech Inc. | Oncolytic viruses and increased cancer treatment regimens |
| KR102607967B1 (ko) * | 2016-12-19 | 2023-11-29 | 메르크 파텐트 게엠베하 | 단백질 키나제 억제제 및 추가 화학요법제의 조합물 |
| CA3060266A1 (en) | 2017-04-17 | 2018-10-25 | Indiana University Research And Technology Corporation | Prevention and reversal of inflammation induced dna damage |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993010076A1 (en) * | 1991-11-22 | 1993-05-27 | The University Of Mississippi | Synthesis and optical resolution of the taxol side chain and related compounds |
| FR2722987B1 (fr) * | 1994-07-29 | 1997-05-16 | Synthelabo | Utilisation de l'eliprodil et de ses enantiomeres pour la preparation de medicaments utiles dans la prevention des neuropathiesinduites par des agentsanticancereux |
| US6025488A (en) * | 1994-11-14 | 2000-02-15 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5789000A (en) | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| DE19617802A1 (de) | 1996-05-03 | 1997-11-06 | Basf Ag | Verfahren zur heterogen katalysierten Herstellung von Hydroxyalkyl-substituierten Aminoalkinen |
| ES2170414T3 (es) | 1996-09-23 | 2002-08-01 | Bionumerik Pharmaceuticals Inc | Reduccion de efectos toxicos del carboplatino usando ditioeteres. |
| US6037336A (en) | 1996-09-23 | 2000-03-14 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
| CN1082047C (zh) | 1996-10-01 | 2002-04-03 | 比奥纽默里克药物公司 | 生产巯基链烷磺酸盐和磷酸盐及其衍生物的方法 |
| US6160167A (en) | 1998-04-21 | 2000-12-12 | Bionumerik Pharmaceuticals, Inc. | Mercaptans and disulfides |
| US6172119B1 (en) | 1999-02-09 | 2001-01-09 | Bionumerik Pharmaceuticals, Inc. | Method of treating acute renal failure |
| US5998479A (en) | 1999-02-09 | 1999-12-07 | Bionumerik Pharmaceuticals, Inc. | Method of treating adult respiratory syndrome |
| US6177411B1 (en) | 1999-02-09 | 2001-01-23 | Bionumerik Pharmaceuticals, Inc. | Method for treating heavy metal poisoning |
| US6197831B1 (en) | 1999-02-09 | 2001-03-06 | Bionumerik Pharmaceuticals, Inc. | Method of treating septic shock |
| US6075053A (en) | 1999-02-09 | 2000-06-13 | Bionumerik Pharmaceuticals, Inc. | Method of reducing or reversing neuropathy |
| US6034126A (en) | 1999-05-24 | 2000-03-07 | Bionumerik Pharmaceuticals, Inc. | Method for treating glycol poisoning |
| US6077838A (en) | 1999-06-08 | 2000-06-20 | Bionumerik Pharmaceuticals, Inc. | Method of treating hangover |
| US6143796A (en) | 1999-09-02 | 2000-11-07 | Bionumerik Pharmaceuticals, Inc. | Method for reducing development of free radical induced malignancies |
| US6468993B1 (en) | 1999-10-04 | 2002-10-22 | Bionumerik Pharmaceuticals, Inc. | Method for reducing development of osteoporosis |
| US6251881B1 (en) | 1999-10-21 | 2001-06-26 | Frederick H. Hausheer | Method of treating diabetic angiopathy |
| US6043274A (en) | 1999-10-21 | 2000-03-28 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic cardiomyopathy |
| US6031006A (en) | 1999-10-21 | 2000-02-29 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic nephropathy |
| US6100247A (en) | 1999-10-21 | 2000-08-08 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic neuropathy |
| US6274622B1 (en) | 1999-10-27 | 2001-08-14 | Frederick H. Hausheer | Method of treating diabetic ophthalmopathy |
| US6525037B1 (en) | 2000-02-25 | 2003-02-25 | Bionumerik Pharmaceuticals, Inc. | Method of treating atherosclerosis and complications resulting therefrom |
| AU2000239101A1 (en) * | 2000-03-22 | 2001-10-03 | Neopharm, Inc. | A method of administering liposomal encapsulated taxane |
| US6245815B1 (en) | 2000-04-15 | 2001-06-12 | Bionumerik Pharmaceuticals, Inc. | Method of treating alcoholism and complications resulting therefrom |
| US6468963B1 (en) | 2000-05-01 | 2002-10-22 | Bionumerik Pharmaceuticals, Inc. | Methods and formulations for reducing toxicity associated with diabetes treatments |
| FR2811987A1 (fr) | 2000-07-18 | 2002-01-25 | Expansia Sa | Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium |
| US6225295B1 (en) | 2000-09-27 | 2001-05-01 | Frederick H. Hausheer | Method of treating acetaminophen overdose |
| US6291441B1 (en) | 2000-09-27 | 2001-09-18 | Frederick H. Hausheer | Method of treating inflammatory bowel disorders |
| US6255355B1 (en) | 2001-01-06 | 2001-07-03 | Seetharamulu Peddaiahgari | Method of inhibiting angiogenesis |
| EP1351677A4 (en) | 2001-01-19 | 2009-08-19 | Bionumerik Pharmaceuticals Inc | CANCER TREATMENT METHOD |
| US6352979B1 (en) | 2001-08-20 | 2002-03-05 | Lucinda Lizcano | Method of treating snakebite and complications resulting therefrom |
| US7176192B2 (en) | 2001-10-26 | 2007-02-13 | Bionumerik Pharmaceuticals, Inc. | Method for treating patients for radiation exposure |
| US6596320B1 (en) | 2002-01-11 | 2003-07-22 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer having greater efficacy and reduced adverse effects |
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US6504049B1 (en) | 2002-04-30 | 2003-01-07 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing pharmaceutically active disulfide salts |
| US20040014730A1 (en) | 2002-07-10 | 2004-01-22 | Frederick Hausheer | Formulations and methods of reducing toxicity of anti-infective agents |
| MXPA05006721A (es) | 2002-12-21 | 2005-09-30 | Bionumerik Pharmaceuticals Inc | Metodo para tratamiento de pacientes expuestos a agentes quimicos toxicos. |
| US20040152774A1 (en) | 2003-02-04 | 2004-08-05 | Hausheer Frederick H. | Method of protecing against tissue extra vasation injury |
| CA2548497C (en) | 2003-12-17 | 2009-06-09 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing disulfides |
-
2002
- 2002-04-30 US US10/135,975 patent/US8710095B2/en not_active Expired - Fee Related
-
2003
- 2003-04-29 ES ES03721972T patent/ES2381968T3/es not_active Expired - Lifetime
- 2003-04-29 WO PCT/US2003/013518 patent/WO2003092675A1/en not_active Ceased
- 2003-04-29 EP EP03721972A patent/EP1503748B1/en not_active Expired - Lifetime
- 2003-04-29 AU AU2003225253A patent/AU2003225253B2/en not_active Ceased
- 2003-04-29 CA CA002483857A patent/CA2483857A1/en not_active Abandoned
- 2003-04-29 JP JP2004500859A patent/JP5416327B2/ja not_active Expired - Fee Related
- 2003-04-29 AT AT03721972T patent/ATE554753T1/de active
-
2011
- 2011-04-13 JP JP2011089619A patent/JP2011140521A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1503748B1 (en) | 2012-04-25 |
| ATE554753T1 (de) | 2012-05-15 |
| AU2003225253A1 (en) | 2003-11-17 |
| US20030203960A1 (en) | 2003-10-30 |
| WO2003092675A1 (en) | 2003-11-13 |
| CA2483857A1 (en) | 2003-11-13 |
| JP2011140521A (ja) | 2011-07-21 |
| US8710095B2 (en) | 2014-04-29 |
| AU2003225253B2 (en) | 2008-09-04 |
| EP1503748A1 (en) | 2005-02-09 |
| EP1503748A4 (en) | 2009-10-21 |
| JP2005525409A (ja) | 2005-08-25 |
| JP5416327B2 (ja) | 2014-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2381968T3 (es) | 2,2'-ditio-bis(etanosulfonato) para su uso en la inhibición de la termoestesia anómala inducida por paclitaxel | |
| ES2215305T3 (es) | Metodos analgesicos usando los catalizadores sinteticos para la dismutacion de los radicales superoxido. | |
| ES2275931T5 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
| EP1115391B1 (en) | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin | |
| CN100411628C (zh) | 空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用 | |
| AU2014251087B2 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| JP2005525409A5 (https=) | ||
| ES2374503T3 (es) | Acetil l-carnitina para la prevención y/o el tratamiento de las neuropatías periféricas inducidas por talidomida. | |
| WO2015191563A1 (en) | Combination chemotherapy comprising a liposomal prodrug of mitomycin c | |
| KR20020060226A (ko) | 배합 화학요법 | |
| JP2009292837A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| ES2761311T3 (es) | Tratamiento terapéutico | |
| EP1273296B1 (en) | Combination of acetyldinaline and docetaxel | |
| ES2896051T3 (es) | Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral | |
| ES2981848T3 (es) | C-ficocianina para usar en el tratamiento y/o la prevención de la neuropatía periférica | |
| JP2023050198A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| JP2013510866A (ja) | 組み合わせたチボザニブおよびテムシロリムス | |
| ES2806449T3 (es) | Fármaco antitumoral que contiene compuesto de taxano y potenciador del efecto antitumoral | |
| KR102308146B1 (ko) | 항암제에 의해 유도되는 이질통의 예방 또는 치료용 조성물 및 이를 이용한 치료방법 | |
| JP2009507071A (ja) | ビタミンｂ１２組成物 | |
| US20030134893A1 (en) | Combination chemotherapy | |
| JP2006518355A (ja) | インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法 | |
| HK1193771A (en) | Therapeutic treatment |